Evidence map›Paper›PMID 29977602›Full record

ArticleNPJ systems biology and applications2018

Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer.

H Alexander Ebhardt, Alex Root, Yansheng Liu, Nicholas Paul Gauthier, Chris Sander, Ruedi Aebersold

Open access · goldAbstract read
In one paragraph

Article in NPJ systems biology and applications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. miR-31-5p RegulatesCancer management and research · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

H Alexander Ebhardt *1Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Auguste Piccard Hof 1, Zürich, Switzerland.ORCID 0000-0001-9019-8388
Alex Root *3Computational Biology Center, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY USA.
Yansheng Liu1Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Auguste Piccard Hof 1, Zürich, Switzerland.
Nicholas Paul Gauthier6cBio Center, Dana-Farber Cancer Institute, Boston, MA USA.
Chris Sander *6cBio Center, Dana-Farber Cancer Institute, Boston, MA USA.
Ruedi Aebersold *1Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Auguste Piccard Hof 1, Zürich, Switzerland.
Harvard University · USMemorial Sloan Kettering Cancer Center · USUniversity College Dublin · IEUniversity of Zurich · CHYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
TR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2012 to 2024
$17.3M
Pathway Commons: Research Resource for Biological PathwaysU41HG006623 · NHGRI · SLOAN-KETTERING INST CAN RESEARCH · PI SANDER, CHRIS · 2012 to 2017
$5.7M
European Research Council 670821NCI NIH HHS P30 CA008748NHGRI NIH HHS U41 HG006623NIGMS NIH HHS P41 GM103504
6 · The paper itself

Abstract

In the United States alone one in five newly diagnosed cancers in men are prostate carcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction pathway are critical in PCa. After initial response to single drugs targeting these pathways resistance often emerges, indicating the need for combination therapy. Here, we address the question of efficacy of drug combinations and development of resistance mechanisms to targeted therapy by a systems pharmacology approach. We combine targeted perturbation with detailed observation of the molecular response by mass spectrometry. We hypothesize that the molecular short-term (24 h) response reveals details of how PCa cells adapt to counter the anti-proliferative drug effect. With focus on six drugs currently used in PCa treatment or targeting the PI3K-AKT-mTOR signal transduction pathway, we perturbed the LNCaP clone FGC cell line by a total of 21 treatment conditions using single and paired drug combinations. The molecular response was analyzed by the mass spectrometric quantification of 52 proteins. Analysis of the data revealed a pattern of strong responders, i.e., proteins that were consistently downregulated or upregulated across many of the perturbation conditions. The downregulated proteins, HN1, PAK1, and SPAG5, are potential early indicators of drug efficacy and point to previously less well-characterized response pathways in PCa cells. Some of the upregulated proteins such as 14-3-3 proteins and KLK2 may be useful early markers of adaptive response and indicate potential resistance pathways targetable as part of combination therapy to overcome drug resistance. The potential of 14-3-3ζ (YWHAZ) as a target is underscored by the independent observation, based on cancer genomics of surgical specimens, that its DNA copy number and transcript levels tend to increase with PCa disease progression. The combination of systematic drug perturbation combined with detailed observation of short-term molecular response using mass spectrometry is a potentially powerful tool to discover response markers and anti-resistance targets.

Identifiers

PMID29977602
PMCPMC6026592
OpenAlexW2809309577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.